Literature DB >> 12732176

Structural and functional characterization of Runx1, CBF beta, and CBF beta-SMMHC.

Lina Zhang1, Stephen M Lukasik, Nancy A Speck, John H Bushweller.   

Abstract

Core binding factors (CBFs) are heterodimeric transcription factors consisting of a DNA-binding CBF alpha subunit and non-DNA-binding CBF beta subunit. DNA binding and heterodimerization is mediated by a single domain in the CBF alpha subunit called the Runt domain, while sequences flanking the Runt domain confer other biochemical activities such as transactivation. On the other hand, the heterodimerization domain in CBF beta is the only functional domain that has been identified in this subunit. The biophysical properties of the Runt domain and the CBF beta heterodimerization domain, and the structures of the isolated domains as well as of the Runt domain-DNA, Runt domain-CBF beta, and ternary Runt domain-CBF beta-DNA complexes, have been characterized over the past several years, and are summarized in this review.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12732176     DOI: 10.1016/s1079-9796(03)00022-6

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  6 in total

1.  HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor β on genetically distinct surfaces.

Authors:  Judd F Hultquist; Rebecca M McDougle; Brett D Anderson; Reuben S Harris
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-13       Impact factor: 2.205

2.  Oct-1 counteracts autoinhibition of Runx2 DNA binding to form a novel Runx2/Oct-1 complex on the promoter of the mammary gland-specific gene beta-casein.

Authors:  Claire K Inman; Na Li; Paul Shore
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

3.  The Runx transcriptional co-activator, CBFbeta, is essential for invasion of breast cancer cells.

Authors:  Daniel Mendoza-Villanueva; Wensheng Deng; Cesar Lopez-Camacho; Paul Shore
Journal:  Mol Cancer       Date:  2010-06-30       Impact factor: 27.401

4.  Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin.

Authors:  Daniel Mendoza-Villanueva; Leo Zeef; Paul Shore
Journal:  Breast Cancer Res       Date:  2011-10-27       Impact factor: 6.466

5.  Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment.

Authors:  Hailati Aini; Keiji Itaka; Ayano Fujisawa; Hirokuni Uchida; Satoshi Uchida; Shigeto Fukushima; Kazunori Kataoka; Taku Saito; Ung-il Chung; Shinsuke Ohba
Journal:  Sci Rep       Date:  2016-01-05       Impact factor: 4.379

6.  PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia.

Authors:  Lulu Wang; Wei Wang; Hannah C Beird; Xueqian Cheng; Hong Fang; Guilin Tang; Gokce A Toruner; C Cameron Yin; M James You; Ghayas C Issa; Gautam Borthakur; Guang Peng; Joseph D Khoury; L Jeffrey Medeiros; Zhenya Tang
Journal:  Genes (Basel)       Date:  2022-07-29       Impact factor: 4.141

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.